MedTrace Logo

Trial of Oxaloacetate in Alzheimer's Disease (TOAD)

NCT02593318 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-07-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).

Conditions

  • Alzheimer's Disease (AD)

Interventions

DRUG

Oxaloacetate (OAA) 1g

Pills to be taken orally in 500mg dose two times per day

DRUG

Oxaloacetate (OAA) 2g

Pills to be taken orally in 1000mg dose two times per day.

Sponsors & Collaborators

  • Russell Swerdlow

    lead OTHER

Principal Investigators

  • Russell Swerdlow, MD · University of Kansas Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02593318 on ClinicalTrials.gov